These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36395396)

  • 1. Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants.
    Shah I; Silva-Santisteban A; Germansky KA; Kandasamy C; Mlabasati J; Huang DC; Wadhwa V; Bilal M; Sawhney MS
    Pancreas; 2022 Aug; 51(7):733-738. PubMed ID: 36395396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.
    Shah I; Silva-Santisteban A; Germansky KA; Wadhwa V; Tung N; Huang DC; Kandasamy C; Mlabasati J; Bilal M; Sawhney MS
    J Clin Gastroenterol; 2023 Mar; 57(3):317-323. PubMed ID: 35220378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.
    Laish I; Schechter M; Dancour A; Lieberman S; Levi Z; Goldberg Y; Kedar I; Hasnis E; Half E; Levi GR; Katz L; Vainer ED; Genzel D; Aharoni M; Chen-Shtoyerman R; Abu-Freha N; Raitses-Gurevich M; Golan T; Bernstein-Molho R; Ben Yehoyada M; Gluck N; Rosner G
    Cancer; 2024 Jan; 130(2):256-266. PubMed ID: 37861363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
    Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
    Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
    Roch AM; Schneider J; Carr RA; Lancaster WP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
    J Surg Oncol; 2019 May; 119(6):777-783. PubMed ID: 30636051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
    Power R; Leavy C; Nolan C; White N; Clarke R; Cadoo KA; Gallagher DJ; Lowery MA
    Fam Cancer; 2021 Apr; 20(2):97-101. PubMed ID: 32918181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
    J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening?
    Roch AM; Kim RC; Nguyen TK; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
    J Surg Oncol; 2023 Aug; 128(2):289-294. PubMed ID: 37083062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
    Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA;
    Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2022 Mar; 104():102357. PubMed ID: 35184001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
    Carnevale J; Ashworth A
    J Clin Oncol; 2015 Oct; 33(28):3080-1. PubMed ID: 25987697
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
    Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
    Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
    Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
    Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
    Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
    PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
    Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
    PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary.
    Kupfer SS; Gupta S; Weitzel JN; Samadder J
    Gastroenterology; 2020 Aug; 159(2):760-764. PubMed ID: 32335146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.